Anebulo Pharmaceuticals, Inc

/Anebulo Pharmaceuticals, Inc

We are a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Our lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration.


Price Range
$6.00 - $8.00

Final Shares

Anticipated Date
May 7, 2021


This offering is no longer available

To view the prospectus for IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange